suMMARY 14 children, aged between 15 months and 14 years, with brucellosis were treated with oral rifampicin only (20 mg/kg per day) for 3 weeks. Laboratory diagnosis depended on blood culture (positive for Bracella melitensis in 11 of the cases), serum agglutination, complement-fixation test, and Coombs's test. Response was good in each child, with fever clearing between the 2nd and 8th day. 2 children relapsed, but one relapse was probably a reinfection from contaminated cheese. Both children were given a further course of treatment (rifampicin and co-trimoxazole) which was successful. Despite the reasonably good results with rifampicin alone, it is advisable to combine the drug with co-trimoxazole when treating brucellosis.
In Spain, brucellosis is still endemic and constitutes a major public health problem.' Treatment of this infection has been unsatisfactory,2 despite the use of such drugs as sulphonamides and streptomycin, and broad spectrum antibiotics-such as chloramphenicol, chlortetracycline, oxytetracycline.Y4
Rifampicin is a broad spectrum antibiotic with potent antibrucellar activity in vitro. rt has been reported to be effective in the treatment of experimental brucellosis.5 Rifampicin is rapidly absorbed by the bowel to give high plasma levels, spreading widely through the body. Because of its neutral molecule it penetrates into the interior of cells and so reaches the reticuloendothelial system, where the brucellar organisms persist, thus causing relapses and chronic illness.6
Materials and methods
We have studied 14 cases of brucellosis in children (9 boys and 5 girls); their ages ranged between 15 months and 14 years. Most came from country areas: 9 from villages, 2 from suburban areas, and only 3 from the city. Except in three cases, the source of infection was almost certainly attributable to the consumption of contaminated milk or cheese.
The variety of symptoms (Table 1 ) was wide. Fever was present initially, often associated with articular and muscular pains. Sweats and weakness were present in half of the children, but not necessarily together. The fever sometimes took an undulant form, but was more often a constant low fever. Splenomegaly was observed in 11 patients and hepatomegaly in 9. A clinical diagnosis of brucellosis was made in Brucellosis treated with rifampicin 487 Relapses. All the patients were followed up. This gave us the opportunity to study two relapses which occurred 3 and 7 weeks after treatment had been stopped. One patient developed an acute arthritis, and in the other the typical clinical picture of acute brucellosis recurred. In both cases blood culture was again positive. The first of these was probably due to the fact that treatment had been stopped without due attention being paid to the child's residual arthritis. The second case was perhaps a reinfection rather than a relapse, because the child continued to eat cheese made from goat's milk, despite our warnings. In both cases, full recovery followed a 21-day course of rifampicin and cotrimoxazole.
Discussion
We found rifampicin to be reasonably effective when used as the sole drug in the treatment of acute brucellosis, 85% of the children being cured by a 21-day course of the drug. It is easy to administer, and side effects are minimal. Furthermore, because of its ability to penetrate the reticuloendothelial system, where the brucellar organisms lodge, relapses and chronic forms of the disease are fewer. Despite these results with rifampicin alone, we think that brucellosis should not be routinely treated with only one antibiotic. We suggest that rifampicin should be combined with co-trimoxazole as currently the most effective treatment.8
